Stock Scorecard



Stock Summary for Capricor Therapeutics Inc (CAPR) - $10.06 as of 8/28/2026 4:06:48 PM EST

Total Score

7 out of 30

Safety Score

21 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CAPR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CAPR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CAPR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CAPR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CAPR (21 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for CAPR

Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026 8/25/2026 11:14:00 PM
Capricor Therapeutics, Inc. (CAPR) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 28, 2026 Lead Plaintiff Deadline 8/25/2026 7:14:00 PM
Capricor Therapeutics stock surges on Oppenheimer upgrade 8/25/2026 3:14:00 PM
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces 8/25/2026 11:43:00 AM
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline 8/24/2026 4:43:00 PM
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA 8/24/2026 1:42:00 PM
Capricor's Duchenne drug gets three-month FDA extension after new data submission 8/24/2026 1:39:00 PM
Capricor Therapeutics Deramiocel PDUFA Date Extended to November as FDA Reviews BLA Amendment 8/24/2026 7:05:00 AM
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026 8/22/2026 6:46:00 PM
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit 8/22/2026 6:46:00 PM

Financial Details for CAPR

Company Overview

Ticker CAPR
Company Name Capricor Therapeutics Inc
Country N/A
Description Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 10.06
Price 4 Years Ago 3.86
Last Day Price Updated 8/28/2026 4:06:48 PM EST
Last Day Volume 12,045,617
Average Daily Volume 10,681,522
52-Week High 40.37
52-Week Low 2.96
Last Price to 52 Week Low 239.86%

Valuation Measures

Trailing PE N/A
Industry PE 36.35
Sector PE 52.46
5-Year Average PE -10.36
Free Cash Flow Ratio 27.94
Industry Free Cash Flow Ratio 34.69
Sector Free Cash Flow Ratio 33.15
Current Ratio Most Recent Quarter 7.35
Total Cash Per Share 0.36
Book Value Per Share Most Recent Quarter 4.24
Price to Book Ratio 1.61
Industry Price to Book Ratio 4.74
Sector Price to Book Ratio 9.24
Price to Sales Ratio Twelve Trailing Months 124.43
Industry Price to Sales Ratio Twelve Trailing Months 30.30
Sector Price to Sales Ratio Twelve Trailing Months 30.53
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 58,139,000
Market Capitalization 584,878,340
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -159.58%
Reported EPS 12 Trailing Months -2.99
Reported EPS Past Year -1.29
Reported EPS Prior Year -2.26
Net Income Twelve Trailing Months -129,416,560
Net Income Past Year -105,043,946
Net Income Prior Year -40,467,186
Quarterly Revenue Growth YOY -7.90%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 20,935,187
Total Cash Past Year 287,847,312
Total Cash Prior Year 11,286,996
Net Cash Position Most Recent Quarter 17,558,928
Net Cash Position Past Year 284,471,053
Long Term Debt Past Year 3,376,259
Long Term Debt Prior Year 3,376,259
Total Debt Most Recent Quarter 3,376,259
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 0.99
Total Stockholder Equity Past Year 305,792,145
Total Stockholder Equity Prior Year 145,462,336
Total Stockholder Equity Most Recent Quarter 246,218,890

Free Cash Flow

Free Cash Flow Twelve Trailing Months -129,778,200
Free Cash Flow Per Share Twelve Trailing Months -2.23
Free Cash Flow Past Year -72,715,722
Free Cash Flow Prior Year -41,534,717

Options

Put/Call Ratio 0.78
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.17
MACD Signal -1.99
20-Day Bollinger Lower Band 19.54
20-Day Bollinger Middle Band 28.10
20-Day Bollinger Upper Band 36.66
Beta 0.53
RSI 27.18
50-Day SMA 20.46
150-Day SMA 12.49
200-Day SMA 10.55

System

Modified 8/28/2026 7:34:16 PM EST